Topics covered include population sampling and generalizability, power and sample size calculations, correction for multiple statistical testing, and how to identify the appropriate use of statistics.
Moreover, the question of multiple statistical testing is correctly addressed: "no adjustment was made for multiple comparisons".
Consequently, multiple statistical testing of several endpoints without or with only insufficient adjustment of the chosen significance level, or the use of inadequate statistical methods [21, 69 71].
We used a Bonferroni correction to account for the fact that we employed multiple statistical testing; a p value of 0.005 was used to signify statistical significance.
In the case of several primary endpoints, for an "A" rating, the problem of multiple statistical testing had to be discussed or considered accordingly in the statistical methodology.
Because of the multiple statistical testing resulting from the numerous variables measured, all results have to be interpreted in an exploratory rather than confirmatory manner.
As multiple statistical testing is not considered in the design of the study, comparisons versus placebo can only be judged as descriptive and do not constitute a confirmatory proof of efficacy.
Consequently, they also clearly violate the CONSORT guidelines [67] regarding interpretation of the results under consideration of the study hypotheses, the possible causes of distortions ("bias") and the problems brought about by multiple statistical testing and multiple target criteria.
The lack of randomization, allocation concealment, blinding, primary outcome and sample size calculation, as well as multiple statistical testing, and publication bias have been assumed to account for the poor translation of AR to human medicine [3],[3],[3],[3]].
Multiple statistical testing is not considered in the design of the study either in the form of a hierarchical test procedure or in the form of a α-adjustment.
In the study design, multiple statistical testing is not considered either in the form of a hierarchical test procedure or in the form of a α-adjustment; thus it does not constitute a confirmatory proof of efficacy for naratriptan 2.5 mg in line with these recommendations.
